Fulvic Acid Skin Conditions

Effects of Fulvic Acid on Skin – A brief literature review – Michael Karr, Ph.d

Fulvic acid has been demonstrated to be useful for a wide variety of skin related conditions: Psoriasis, eczema, seborrheic keratosis, pruritis and actinic keratosis Has anti-bacterial, anti-fungal, and anti-viral properties. Has anti-inflammatory and anti-allergic properties. Stimulates healing. Useful in treatment of allergic diseases. Anti-mutagenic and anti-clastigenic effects, preventing genetic material from mutating – a key factor in skin cancer prevention

https://pdfs.semanticscholar.org/7444/ac717fe63124d0bc952d52c8567dca65c52b.pdf

____________________________

SKIN / Bath Therapies 

Fulvic acid and Humic extract topical use and bath therapies show amazing clinical results Fulvic acid and humic extract water solutions can safely be applied as skin treatments. Directly applied or as bath therapies, fulvic and humic extracts are safe in amounts as high as 10 percent weight-by-volume. Medical doctors have found that extended saturation of the skin by direct application, or use as a bath therapy can be highly successful in treating many external and internal conditions. Clinical studies show that ulcerous skin problems and various skin diseases can be eliminated. Studies by a U.S. doctor have shown that fulvic acid or humic extract bath treatments can cure the common cold or flu in just one or two session, stopping them dead in their tracks. 

Hospital patients with skin ulcers had 92.2% success rate when treated with fulvic acid and humic extract baths.

Yuan, Shenyuan; Fulvic Acid, 4 1988; in Application of Fulvic acid and its derivatives in the fields of agriculture and medicine; First Edition: June 1993  

____________________________

Carbohydrate-derived fulvic acid is a highly promising topical agent to enhance healing of wounds infected with drug-resistant pathogens. 

CHD-FA showed strong activity against a variety of bacterial and fungal pathogens with minimum inhibitory concentration values equal or less than 0.5%. Compared with infected but untreated wounds, improved wound healing upon CHD-FA treatment was observed in both infection models, demonstrated by wound surface area measurement, histopathologic examination, and expression profiling of wound healing genes. Up-regulation of proinflammatory cytokine interleukin 6 (IL-6) at Day 3 after infection was significantly dampened at Days 6 and 10 in the CHD-FA-treated wounds in both infection models, displaying an improved and accelerated wound healing. 

CHD-FA is a promising topical remedy for drug-resistant wound infections. It accelerated the healing process of wounds infected with methicillin-resistant S. aureus and multidrug-resistant P. aeruginosa in rats, which is linked to both its antimicrobial and anti-inflammatory properties. 

https://www.ncbi.nlm.nih.gov/pubmed/26406424

_________________________

Skin / Eczema 

Randomized, parallel-group, double-blind, controlled study to evaluate the efficacy and safety of carbohydrate-derived fulvic acid in topical treatment of eczema 

The purpose of this study was to evaluate the efficacy and safety of carbohydrate derived fulvic acid (CHD-FA) in the treatment of eczema in patients two years and older. CHD-FA was well tolerated, with no difference in reported side effects other than a short-lived burning sensation on application. CHD-FA significantly improved some aspects of eczema. Investigator assessment of global response to treatment with CHD-FA was significantly better than that with emollient therapy alone. The results of this small exploratory study suggest that CHD-FA warrants further investigation in the treatment of eczema. 

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3173016/

References 

1. Snyman JR, Dekker J, Malfeld SCK, van Rensburg CEJ. Pilot study to evaluate the safety and therapeutic efficacy of topical oxifulvic acid in atopic volunteer. Drug Dev Res. 2002;57:40–43. 

2. Van Rensburg CEJ, Malfeld SCK, Dekker J. Topical application of oxifulvic acid suppresses the cutaneous immune response in mice. Drug Dev Res. 2001;53:29–32. 

3. van Rensburg CEJ, Van Straten A, Dekker J. An in vitro investigation of the antimicrobial activity of oxifulvic acid. J Antimicrob Chemother. 2000;46:853. [PubMed] 

4. Vrey PJ, Jansen van Rensburg CEJ. Characterization of a novel fulvic acid product derived from a safe, metal-free, naturally-occurring carbohydrate source. Data on file at Department of Pharmacology, University of Pretoria; Pretoria, South Africa: 

5. Levin OL, Silvers SE. The reaction of the skin and its secretions in eczema. Arch Derm Syphilol. 1932;25:825–834. 

6. Chikakane K, Takahashi H. Measurement of skin pH and its significance in cutaneous diseases. Clin Dermatol. 1995;13:299–306. [PubMed] 

7. Barbier N, Paul C, Luger T, Allen R. Validation of the Eczema Area and Severity Index for atopic dermatitis in a cohort of 1550 patients from the pimecrolimus cream 1% randomized controlled clinical trials programme. Br J Dermatol. 2004;150:96–102. [PubMed] 

8. Faghihi G, Iraji F, Shahingohar A, Saidat AH. The efficacy of ‘0.05% Clobetasol + 2.5% zinc sulphate’ cream vs ‘0.05% Clobetasol alone’ cream in the treatment of the chronic hand eczema: Double-blind study. J Eur Acad Dermatol Venereol. 2008;22:531–536. [PubMed] 

___________________________________________________________